| CTAS |
Report |
Q4 FY2026 revenue |
IN-LINE |
pred ~$2.89B vs. cons $2.88B |
MEDIUM |
| CTAS |
Report |
Q4 FY2026 adjusted diluted EPS |
BEAT |
pred ~$1.25 vs. cons $1.23 |
MEDIUM |
| CTAS |
Report |
Q4 FY2026 organic revenue growth |
BEAT |
pred ~7.8% vs. cons 7.6% |
MEDIUM |
| CTAS |
Guide |
FY2027 revenue |
LOWER |
guide ~$12.03B midpoint vs. cons $12.07B (FY2027) |
MEDIUM |
| CTAS |
Guide |
FY2027 adjusted diluted EPS |
LOWER |
guide ~$5.33 midpoint vs. cons $5.43 (FY2027) |
MEDIUM |
| CTAS |
Guide |
FY2027 organic revenue growth |
LOWER |
guide ~7.0% midpoint vs. cons 7.4% (FY2027) |
MEDIUM |
| CTAS |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.8% |
— |
MEDIUM |
| CTAS |
Return |
5-day cumulative residual |
-4.2% (FOLLOW-THROUGH) |
A modest Q4 EPS beat of ~$1.25 vs. $1.23 is outweighed by FY2027 EPS guidance of ~$5.33 vs. $5.43 and revenue guidance of ~$12.03B vs. $12.07B, prompting out-period estimate cuts after the pre-earnings rally. |
MEDIUM |